Physician profile
Ashish Haryani
NPI 1245556547
$37,819.44
in general payments reported to CMS, 2019-2025
27 companies · $15K in 2025
The $15K reported for 2025 was more than what 81% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,227 · 2020: $2,210 · 2021: $944 · 2022: $168 · 2023: $1,607 · 2024: $12K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $4,292 · Travel and Lodging: $2,226 · Consulting Fee: $750 · Education: $61.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,940.00 |
| Food and Beverage | $4,292.38 |
| Travel and Lodging | $2,225.51 |
| Consulting Fee | $750.00 |
| Education | $61.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,762.70 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $8,203.69 | 2019-2025 | |
| Abbott Laboratories | $5,180.79 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Lilly USA, LLC | $3,965.00 | 2024-2025 | Jardiance |
| United Therapeutics Corporation | $312.00 | 2019-2024 | Orenitram, Tyvaso, Remodulin |
| Abiomed | $295.97 | 2023-2025 | Impella |
| Livanova USA, INC. | $229.00 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $225.42 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $218.93 | 2022-2025 | Farxiga, Wainua, Brilinta |
| Merck Sharp & Dohme LLC | $182.08 | 2023-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $181.92 | 2024-2025 | Onpattro |
| Edwards Lifesciences Corporation | $181.29 | 2024-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $142.06 | 2023-2025 | Abilify, Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $114.30 | 2024-2025 | |
| Cvrx, INC. | $93.96 | 2025 | Barostim Neo System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ancora Heart, INC. | $81.45 | 2023 | Accucinch |
| Pfizer INC. | $68.92 | 2025 | |
| Medtronic, INC. | $57.49 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $55.79 | 2019-2023 | Uptravi |
| Kestra Medical Technology Services, INC. | $52.28 | 2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $47.51 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $46.20 | 2025 | Uptravi, Opsynvi |
| Scpharmaceuticals INC. | $40.24 | 2023-2024 | |
| Bridgebio Pharma, INC. | $33.06 | 2025 | Attruby |
| Daxor Corporation | $27.88 | 2023 | Bva-100 |
| Novo Nordisk INC | $19.51 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Haryani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.